Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment : case report
Blocking integrin binding to fibronectin by a monoclonal antibody directed to integrin receptors induces apoptosis of proliferating endothelial cells. We report a case of grade 2 proteinuria, occurred fifteen days after the first administration of an anti-integrin monoclonal antibody associated to standard doses of carboplatin/paclitaxel and to a single dose of zoledronic acid in a patient treated in first line setting for a metastatic non small cell lung cancer. Kidney biopsy revealed a tubular damage probably associated to minimal change glomerulonephritis. Even if this patient did not receive any further dose of zoledronic acid, proteinuria reoccurred, although at a lower level when the investigational drug was reintroduced at the same dose. Renal function remained normal. The patient received two further cycles with lower doses, without recurrence of proteinuria. These findings suggest that this type of integrin antibody may induce transient urinary excretion of protein in a dose dependent manner without adversely affecting renal function.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2010 |
|---|---|
| Erschienen: |
2010 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Investigational new drugs - 28(2010), 1 vom: 21. Feb., Seite 102-5 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gombos, Andrea [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 23.03.2010 Date Revised 20.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10637-009-9247-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM187616612 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM187616612 | ||
| 003 | DE-627 | ||
| 005 | 20231223180357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2010 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10637-009-9247-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0625.xml |
| 035 | |a (DE-627)NLM187616612 | ||
| 035 | |a (NLM)19343274 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gombos, Andrea |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment |b case report |
| 264 | 1 | |c 2010 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.03.2010 | ||
| 500 | |a Date Revised 20.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Blocking integrin binding to fibronectin by a monoclonal antibody directed to integrin receptors induces apoptosis of proliferating endothelial cells. We report a case of grade 2 proteinuria, occurred fifteen days after the first administration of an anti-integrin monoclonal antibody associated to standard doses of carboplatin/paclitaxel and to a single dose of zoledronic acid in a patient treated in first line setting for a metastatic non small cell lung cancer. Kidney biopsy revealed a tubular damage probably associated to minimal change glomerulonephritis. Even if this patient did not receive any further dose of zoledronic acid, proteinuria reoccurred, although at a lower level when the investigational drug was reintroduced at the same dose. Renal function remained normal. The patient received two further cycles with lower doses, without recurrence of proteinuria. These findings suggest that this type of integrin antibody may induce transient urinary excretion of protein in a dose dependent manner without adversely affecting renal function | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Integrins |2 NLM | |
| 700 | 1 | |a Izzedine, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Besse, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Massard, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Brocheriou, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Bahleda, Rastislav |e verfasserin |4 aut | |
| 700 | 1 | |a Soria, Jean-Charles |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Investigational new drugs |d 1993 |g 28(2010), 1 vom: 21. Feb., Seite 102-5 |w (DE-627)NLM013000160 |x 1573-0646 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2010 |g number:1 |g day:21 |g month:02 |g pages:102-5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10637-009-9247-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2010 |e 1 |b 21 |c 02 |h 102-5 | ||